Novel guanosine monophosphate synthetase inhibitors as therapeutic agents

By developing a new guanosine monophosphate synthase inhibitor, the toxicity and selectivity problems of existing GMPS inhibitors in the treatment of cancer and viral infections have been solved, and efficient GMPS inhibition and cancer cell killing effects have been achieved.

CN113195470BActive Publication Date: 2024-12-03UNIV OF SOUTHERN CALIFORNIA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN201980060242.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-09-13
Filing Date
2019-07-12
Publication Date
2024-12-03
Estimated Expiration
2039-07-12

AI Technical Summary

Technical Problem

The lack of effective and specificity of existing guanosine monophosphate synthase (GMPS) inhibitors lead to toxicity and selectivity problems in the treatment of cancer and viral infections.

Method used

A novel guanosine monophosphate synthase inhibitor was developed, with a compound structure of 2-chloro-N-(4-((3-(prop-2-ynyl-1-yloxy)phenyl)amino)quinazole Lin-6-yl)acetamide or an analog thereof inhibits its enzymatic activity by covalently binding to specific domains of GMPS.

Benefits of technology

These novel inhibitors showed efficient inhibition of GMPS enzyme activity, had low IC50 values, and specifically covalently bound in living cells, significantly reducing cancer cell survival and demonstrating broad-spectrum anti-cancer activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_5
    Figure SMS_5
Patent Text Reader

Abstract

The present invention provides a series of GMPS enzyme inhibitors. The present invention comprises effective GMPS inhibitors, which specifically and covalently bind to GMPS, exhibit broad anticancer activity, block viral infection efficiency and have the potential to inhibit undesirable immune responses. These novel GMPS inhibitors and their derivatives have great potential for use as therapeutic agents for the treatment of cancer, viral infections and immune disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Serial No. 62 / 730,871, filed on September 13, 2018, the entire contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present invention relates generally to GMP synthetase inhibitors and more particularly to the use of novel GMP synthetase inhibitors for treating diseases or disorders and as immunosuppressants.

[0004] Government support

[0005] This invention was made with government support under Grant CHE-1455306 awarded by the National Science Foundation. The government has certain rights in this invention. Background Art

[0006] The de novo biosynthetic pathway of guanosine monophosphate (GMP) involves the conversion of inosine monophosphate (IMP) first into xanthosine monophosphate (XMP) and then into GMP, the latter step being catalyzed by an enzyme, guanosine monophosphate synthetase (GMPS). GMPS is a two-domain enzyme consisting of a glutamine amidotransferase domain (GAT) and a synthetase domain. The GAT domain hydrolyzes glutamine to produce ammonia, which is transferred to the synthetase domain to react with nucleotide intermediates to produce GMP, an important precursor and structural unit of RNA and DNA in cells. Therefore, GMPS plays an important role in cell division and proliferation, as well as viral infection.

[0007] Human GMPS synthase has been identified as a potential target for anticancer therapy. GMPS levels in metastatic melanomas have been shown to be increased compared to primary melanomas. Many studies have demonstrated that GMPS plays an important role in tumor invasion in human metastatic melanomas. Importantly, it has been demonstrated that GMPS inhibition leads to reduced tumor invasion and tumorigenesis.

[0008] GMPS have also been identified as attractive targets for immunosuppressive therapy, specifically in the clinical setting of organ transplantation and lupus. One of the main strategies for immunosuppression involves inhibition of the de novo purine synthesis pathway, in particular de novo GMP synthesis inhibition to prevent GTP and dGTP production. Although the salvage pathway is able to produce some GMP after de novo synthesis is blocked in many cell types, B and T lymphocytes lack important enzymes of the salvage pathway and rely heavily on de novo purine biosynthesis for proliferation.

[0009] In addition to its roles in cancer and immunity mentioned above, GMPS also regulates viral infection. As an important player in de novo GMP biosynthesis, GMPS generates a large pool of purine nucleotides required for viral genome replication. It is therefore believed that inhibition of GMPS will combat viral infection.

[0010] Existing GMPS inhibitors are glutamine analogs or nucleoside analogs, which can simulate substrates and compete with the substrates to bind to the active site of GMPS. For example, acivicin is a glutamine analog that inhibits GMPS by covalently binding to the GAT domain. Because there are a variety of enzymes that utilize glutamine or nucleotides as substrates, these inhibitors that mimic substrates tend to bind to a variety of enzymes and show low selectivity to GMPS. In the past, this became the basis for its toxicity when evaluating the therapeutic application of a variety of GMPS inhibitors. The lack of effective and specific GMPS inhibitors severely limits the use of GMPS as a target in therapeutic applications. Summary of the invention

[0011] The present invention is based on the groundbreaking discovery of novel inhibitors of guanosine monophosphate synthetase and the use of said inhibitors for treating diseases and disorders including cancer and viral infections. In addition, the disclosed inhibitors can be used to suppress an immune response in a subject.

[0012] In one embodiment, the present invention provides a compound of formula (I)

[0013]

[0014] or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof, wherein X is N or CH, R1 is alkyl, acyl, alkoxy, halo, amino, amide, alkenyl or alkynyl; and R2 is alkyl, acyl; alkoxy, halo, amino, amide, alkenyl or alkynyl.

[0015] In another embodiment, the present invention provides a compound of formula (II)

[0016]

[0017] or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof, wherein R1 is alkyl, acyl, alkoxy, halo, amino, amide, alkenyl or alkynyl; and R2 is alkyl, acyl, alkoxy, halo, amino, amide, alkenyl or alkynyl.

[0018] In certain aspects, the compound is

[0019] or a pharmaceutically acceptable salt thereof.

[0020] In other aspects, the compound is

[0021] or a pharmaceutically acceptable salt thereof.

[0022] In certain aspects, the compound is 2-chloro-N-(4-((3-(prop-2-yn-1-yloxy)phenyl)amino)quinazolin-6-yl)acetamide; 2-chloro-N-(4-((3-methoxyphenyl)amino)quinazolin-6-yl)acetamide; N-(4-((3-methoxyphenyl)amino)quinazolin-6-yl)acetamide; 3-(2-chloroacetamido)-N-(3-(prop-2-yn-1-yloxy)phenyl)benzamide; or N-(3-(2-chloroacetamido)phenyl)-3-(prop-2-yn-1-yloxy)benzamide.

[0023] In another embodiment, the present invention provides a method for treating a disease or condition, wherein the method is by administering a compound of formula (I) or formula (II) as provided above, thereby treating the disease condition. In one aspect, the compound is at least one of compounds 1-5 as provided above.

[0024] In various aspects, the disease or illness is cancer or viral infection. In some aspects, the cancer is leukemia, non-small cell lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer and / or breast cancer. In other aspects, the viral infection is gastroenteritis, fatal encephalitis, encephalitis, fever, arthralgia, meningitis, myocarditis, paralysis, hemorrhagic fever, thrombocytopenia, common cold, mononucleosis, kidney or respiratory syndrome, hepatitis, pneumonia, diarrhea, neurological disorders, skin lesions, cutaneous lymphoma, AIDS, skin warts, genital warts, cervical cancer, leukemia, influenza, rash, Merkel cell carcinoma (Merkel cell carcinoma), mumps, poliomyelitis, rubella, Pogosta disease (Pogostadisease), chickenpox and / or smallpox. In other aspects, the method further comprises the use of chemotherapeutic agents or antiviral agents. In various aspects, the compound is used before, simultaneously or afterwards when the chemotherapeutic agents or antiviral agents are used. In certain aspects, the compounds inhibit guanosine monophosphate synthetase.

[0025] In further embodiments, the present invention provides a method of suppressing an immune response in a subject, the method comprising administering a compound of formula (I) or formula (II) as provided above, thereby suppressing the immune response.

[0026] In one aspect, the disease or condition is cancer or viral infection. In one aspect, the compound is at least one of compounds 1-5 as provided above. In various aspects, the subject suffers from an autoimmune disorder, an inflammatory disorder, ankylosing spondylitis, or has an organ and tissue transplant. In certain aspects, the compound inhibits guanosine monophosphate synthase.

[0027] In yet another embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) as provided above and a pharmaceutically acceptable carrier. In one aspect, the compound is at least one of compounds 1-5 as provided above. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 is a schematic representation of the de novo biosynthetic pathway for GMP, demonstrating the role of the two-domain enzyme GMPS and highlighting the role of GMPS in cell division and proliferation and in viral infection.

[0029] Figure 2 The general chemical structures of the novel GMPS inhibitors are shown.

[0030] Figure 3 The compound structures of five novel GMPS inhibitors are shown.

[0031] Figure 4A-4B Compound 1 is shown to efficiently and selectively covalently bind to GMPS in living cells. 4A. Fluorescence images of whole cells labeled with various concentrations of compound 1 in an SDS PAGE gel. 4B. The 75 kDa band was identified as GMPS by liquid chromatography / mass spectrometry analysis.

[0032] Figure 5 is a bar graph showing the survival of eight different cancer cell lines in the presence of Compound 1. HL-60(TB): leukemia; NCI-H23: non-small cell lung cancer; HT29: colon cancer; SF-539: central nervous system cancer; SK-MEL-5: melanoma; OVCAR-5: ovarian cancer; UO-31: renal cancer; BT-549: breast cancer. DETAILED DESCRIPTION

[0033] The present invention is based on the groundbreaking discovery of novel inhibitors of guanosine monophosphate synthetase and the use of said inhibitors for treating diseases and disorders including cancer and viral infections. In addition, the disclosed inhibitors can be used to suppress an immune response in a subject.

[0034] Before describing the compositions and methods of the present invention, it should be understood that the present invention is not limited to the specific compositions, methods and experimental conditions described, as such compositions, methods and conditions may vary. It should also be understood that the terminology used herein is only for the purpose of describing specific embodiments, and is not intended to be limiting, as the scope of the present invention is limited only in the appended claims.

[0035] As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "the method" includes one or more methods and / or steps of the type described herein that will become apparent to one skilled in the art upon reading this disclosure etc.

[0036] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0037] The meaning of all technical terms and scientific terms used herein is the same as that commonly understood by those of ordinary skill in the art to which the present invention belongs, unless otherwise defined. Although any methods and materials similar or equivalent to the methods and materials described herein may be used to practice or test the present invention, it should be understood that modifications and variations are encompassed within the spirit and scope of the present disclosure. Preferred methods and materials are now described.

[0038] The present invention generally relates to small molecule inhibitors of guanosine monophosphate synthase. Table 1 shows the structures of compounds of formula (I) and formula (II). Table 2 shows the structures of compounds 1-5.

[0039] Table 1: General structure

[0040]

[0041] Table 2: Compound structures

[0042]

[0043]

[0044] In one embodiment, the present invention provides a compound of formula (I) or formula (II) as provided in Table 1, or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof, wherein X is N or CH; R1 is alkyl, acyl, alkoxy, halo, amino, amide, alkenyl and alkynyl; and R2 is alkyl, acyl, alkoxy, halo, amino, amide, alkenyl and alkynyl.

[0045] As used herein, the term "alkyl" refers to a straight or branched saturated aliphatic group with the indicated number of carbon atoms. Alkyl can contain any number of carbons, such as C1-2, C1-3, C1-4, C1-5, C1-6, C1-7, C1-8, C1-9, C1-10, C2-3, C2-4, C2-5, C2-6, C3-4, C3-5, C3-6, C4-5, C4-6 and C5-6. For example, C1-6 alkyl includes but is not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, isopentyl, hexyl, etc. Alkyl can also refer to an alkyl with up to 20 carbon atoms, such as but not limited to heptyl, octyl, nonyl, decyl, etc. Alkyl can be substituted or unsubstituted.

[0046] As used herein, the term "alkoxy" refers to an alkyl group with an oxygen atom connecting the alkyl group to the point of attachment: alkyl-O-. For alkyl groups, the alkoxy group can have any suitable number of carbon atoms, such as C1-6. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 2-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, etc. Alkoxy groups can be further substituted with various substituents as described therein. Alkoxy groups can be substituted or unsubstituted.

[0047] As used herein, the term "halogen" refers to fluorine, chlorine, bromine and iodine.

[0048] As used herein, the term "haloalkyl" refers to an alkyl as defined above, wherein some or all of the hydrogen atoms are replaced by halogen atoms. For alkyl, haloalkyl can have any suitable number of carbon atoms, such as C1-6. For example, haloalkyl includes trifluoromethyl, fluoromethyl, etc. In some cases, the term "perfluoro" can be used to define a compound or group in which all hydrogens are replaced by fluorine. For example, perfluoromethane refers to 1,1,1-trifluoromethyl.

[0049] As used herein, the term "haloalkoxy" refers to an alkoxy group in which some or all of the hydrogen atoms are replaced by halogen atoms. For alkyl, haloalkoxy can have any suitable number of carbon atoms, such as C1-6. Alkoxy can be replaced by 1, 2, 3 or more halogens. When all hydrogens are replaced by halogen (e.g., fluorine), the compound is fully substituted, such as perfluorinated. Haloalkoxy includes but is not limited to trifluoromethoxy, 2,2,2,-trifluoroethoxy, perfluoroethoxy etc.

[0050] As used herein, the term "heteroalkyl" refers to an alkyl group with any suitable length and with 1 to 3 heteroatoms (such as N, O and S). Additional heteroatoms may also be useful, including but not limited to B, Al, Si and P. Heteroatoms may also be oxidized, such as but not limited to-S(O)- and-S(O)2-. For example, heteroalkyl groups may include ethers, thioethers and alkylamines. The heteroatom moiety of heteroalkyl groups may replace the hydrogen of an alkyl group to form a hydroxyl, sulfenyl or amino group. Alternatively, the heteroatom moiety may be a connecting atom or may be inserted between two carbon atoms.

[0051] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic, fused bicyclic or bridged polycyclic assembly containing 3 to 12 ring atoms or the number of atoms indicated. Alkyl can contain any number of carbons, such as C3-6, C4-6, C5-6, C3-8, C4-8, C5-8, C6-8, C3-9, C3-10, C3-11 and C3-12. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2] bicyclooctane, decalin and adamantane. Cycloalkyl can also be partially unsaturated, with one or more double bonds or triple bonds in the ring. Partially unsaturated representative cycloalkyl groups include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene (1,3-, 1,4- and 1,5-isomers), norbornene and norbornadiene. When the cycloalkyl group is a saturated monocyclic C3-8 cycloalkyl group, exemplary groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. When the cycloalkyl group is a saturated monocyclic C3-6 cycloalkyl group, exemplary groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl group may be substituted or unsubstituted.

[0052] As used herein, the term "cycloalkylene" refers to a cycloalkyl (i.e., a divalent hydrocarbon group) that is connected to at least two other groups as defined above. The two parts connected to the cycloalkylene can be connected to the same atom or different atoms of the cycloalkylene. Representative cycloalkylene includes but is not limited to cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene and cyclooctylene. The cycloalkylene can be substituted or unsubstituted.

[0053] As used herein, the term "heterocycloalkyl" refers to a saturated ring system having 3 to 12 ring members and 1 to 4 heteroatoms of N, O and S. Additional heteroatoms may also be useful, including but not limited to B, Al, Si and P. Heteroatoms may also be oxidized, such as but not limited to -S(O)- and -S(O)2-. Heterocycloalkyl may contain any number of ring atoms, such as 3 to 6, 4 to 6, 5 to 6, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 3 to 9, 3 to 10, 3 to 11 or 3 to 12 ring members. Any suitable number of heteroatoms may be contained in the heterocycloalkyl, such as 1, 2, 3 or 4, or 1 to 2, 1 to 3, 1 to 4, 2 to 3, 2 to 4 or 3 to 4. Heterocycloalkyl groups may include groups such as aziridine, azetidine, pyrrolidine, piperidine, azepane, azocane, quinuclidine, pyrazolidine, imidazolidine, piperazine (1,2-, 1,3- and 1,4-isomers), oxirane, oxetane, tetrahydrofuran, oxirane (tetrahydropyran), oxepane, thioethane, thietane, thiolane (tetrahydrothiophene), thiane (tetrahydrothiopyran), oxazolidine, isoxalidine, thiazolidine, isothiazolidine, dioxolane, dithiolane, morpholine, thiomorpholine, dioxane or dithiane. Heterocycloalkyl groups may also be fused with aromatic or non-aromatic ring systems to form members including, but not limited to, dihydroindole. Heterocycloalkyl groups may be unsubstituted or substituted. For example, the heterocycloalkyl group may be substituted with a C1-6 alkyl group or an oxy group (=O) or the like.

[0054] The heterocycloalkyl group may be attached at any position on the ring. For example, the aziridine may be 1- or 2-aziridine, the azetidine may be 1- or 2-azetidine, the pyrrolidine may be 1-, 2- or 3-pyrrolidine, the piperidine may be 1-, 2-, 3- or 4-piperidine, the pyrazolidine may be 1-, 2-, 3- or 4-pyrazolidine, the imidazolidine may be 1-, 2-, 3- or 4-imidazolidine, the piperazine may be 1-, 2-, 3- or 4-piperazine, the tetrahydrofuran may be 1- or 2-tetrahydrofuran, the oxazolidine may be 2-, 3-, 4- or 5-oxazolidine, the isoxazolidine may be 2-, 3-, 4- or 5-isoxazolidine, the thiazolidine may be 2-, 3-, 4- or 5-thiazolidine, the isothiazolidine may be 2-, 3-, 4- or 5-isothiazolidine, and the morpholine may be 2-, 3- or 4-morpholine.

[0055] When heterocycloalkyl contains 3 to 8 ring members and 1 to 3 heteroatoms, representative members include but are not limited to pyrrolidine, piperidine, tetrahydrofuran, ethylene oxide, tetrahydrothiophene, cyclopentyl sulfide, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, morpholine, thiomorpholine, dioxane and dithiane. Heterocycloalkyl can also form a ring with 5 to 6 ring members and 1 to 2 heteroatoms, wherein representative members include but are not limited to pyrrolidine, piperidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine and morpholine.

[0056] As used herein, the term "aryl" refers to an aromatic ring system having any suitable number of ring atoms and any suitable number of rings. The aryl group can contain any suitable number of ring atoms (such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms) and 6 to 10, 6 to 12 or 6 to 14 ring members. The aryl group can be monocyclic, fused to form a bicyclic or tricyclic group, or connected by a bond to form a biaryl group. Representative aryl groups include phenyl, naphthyl and biphenyl. Other aryl groups include benzyl with a methylene linking group. Some aryl groups have 6 to 12 ring members, such as phenyl, naphthyl or biphenyl. Other aryl groups have 6 to 10 ring members, such as phenyl or naphthyl. Some other aryl groups have 6 ring members, such as phenyl. The aryl group can be substituted or unsubstituted.

[0057] As used herein, the term "salt" refers to an acid salt or alkaline salt of a compound used in the method of the present invention. Illustrative examples of pharmaceutically acceptable salts are inorganic acid (hydrochloric acid, hydrobromic acid, phosphoric acid, etc.) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid, etc.) salts, quaternary ammonium (methyl iodide, ethyl iodide, etc.) salts. It should be understood that pharmaceutically acceptable salts are non-toxic. Additional information about suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, Pennsylvania, 1985, which is incorporated herein by reference.

[0058] Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, i.e., cationic salts, such as alkali metal salts and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium and ammonium salts, such as ammonium, trimethylammonium, diethylammonium and tris-(hydroxymethyl)-methyl-ammonium salts.

[0059] Similarly, acid addition salts such as inorganic acids, organic carboxylic acids and organic sulfonic acids (eg, hydrochloric acid, methanesulfonic acid, maleic acid) are also possible to provide basic groups such as pyridyl as part of the structure.

[0060] The neutral form of the compound can be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties (such as solubility in polar solvents), but for purposes of the present invention, the salt is equivalent to the parent form of the compound.

[0061] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are intended to be encompassed within the scope of the present invention.

[0062] As used herein, the term "hydrate" refers to a compound that is complexed with at least one water molecule. The compounds of the present invention may be complexed with 1 to 10 water molecules.

[0063] In certain aspects, the compound is at least one of compounds 1-5 or an optically pure stereoisomer or pharmaceutically acceptable salt thereof as shown in Table 2. In other aspects, the compound is 2-chloro-N-(4-((3-(prop-2-yn-1-yloxy)phenyl)amino)quinazolin-6-yl)acetamide; 2-chloro-N-(4-((3-methoxyphenyl)amino)quinazolin-6-yl)acetamide; N-(4-((3-methoxyphenyl)amino)quinazolin-6-yl)acetamide; 3-(2-chloroacetamido)-N-(3-(prop-2-yn-1-yloxy)phenyl)benzamide; or N-(3-(2-chloroacetamido)phenyl)-3-(prop-2-yn-1-yloxy)benzamide.

[0064] In another embodiment, the present invention provides a method for treating a disease or condition in a subject, the method comprising administering to the subject a compound of formula (I) or formula (II) as provided in Table 1, or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof, thereby treating the disease condition. In one aspect, the compound is at least one of compounds 1-5 or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof as shown in Table 2.

[0065] The term "treatment" is used interchangeably herein with the term "therapeutic method" and refers to 1) a therapeutic treatment or measure that cures, slows, alleviates the symptoms of, and / or halts the progression of a diagnosed pathological condition, disease, or disorder, and 2) both preventative / prophylactic measures. Patients in need of treatment may include individuals who already have a particular medical disease or disorder as well as individuals who may eventually acquire the disorder (i.e., individuals in need of preventative measures).

[0066] As used herein, the term "subject" refers to any individual or patient on whom the subject methods are performed. Typically, the subject is a human, but as will be appreciated by those skilled in the art, the subject can be an animal.

[0067] The terms "therapeutically effective amount", "effective dose", "therapeutically effective dose", "effective amount" and the like refer to the amount of the subject compound that induces a biological or medical response in a tissue, system, animal or human by administering the compound. Typically, the response is an improvement in patient symptoms or a desired biological outcome. Such an amount should be sufficient to inhibit GMPS enzyme activity.

[0068] The term "administration of" and or "administering" is understood to refer to providing a therapeutically effective amount of a pharmaceutical composition to a subject in need of treatment. The route of administration may be enteral, topical or parenteral. Thus, routes of administration include but are not limited to intradermal, subcutaneous, intravenous, intraperitoneal, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, transdermal, transtracheal, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal, oral, sublingual, buccal, rectal, vaginal, nasal, ocular administration, as well as infusion, inhalation and atomization.

[0069] In various aspects, the disease or condition is cancer or a viral infection.

[0070] The term "cancer" refers to a group of diseases characterized by abnormal and uncontrolled cell proliferation that begins at one site (primary site), which may invade and spread to other sites (secondary sites, metastases), which distinguishes cancer (malignant tumors) from benign tumors. Almost all organs may be affected, resulting in more than 100 types of cancer that may affect humans. Cancer may be caused by a variety of causes, including genetic susceptibility, viral infection, exposure to ionizing radiation, exposure to environmental pollutants, smoking and / or drinking, obesity, poor diet, lack of physical activity or any combination thereof.

[0071] Exemplary cancers described by the National Cancer Institute include: acute lymphoblastic leukemia, adults; acute lymphoblastic leukemia, children; acute myeloid leukemia, adults; adrenocortical carcinoma; adrenocortical carcinoma, children; AIDS-related lymphoma; AIDS-related malignancies; anal cancer; cerebellar astrocytoma, children; cerebral astrocytoma, children; extrahepatic bile duct carcinoma; bladder cancer; bladder cancer, children; bone cancer, osteosarcoma / malignant fibrous histiocytoma; brain stem glioma, children; brain tumor, adult; brain tumor, brain stem glioma, children; brain tumor , Cerebellar Astrocytoma, Childhood; Brain Tumor, Cerebral Astrocytoma / Malignant Glioma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumor, Childhood; Brain Tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor (Other), Childhood; Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenoma / Carcinoid, Childhood; Carcinoid Tumor, Childhood; Gastrointestinal Carcinoid Tumor; Adrenal Cortical Carcinoma; Islet Cell Carcinoma; Tumor of Unknown Primary; Primary Central Nervous System Lymphoma, Childhood Cerebellar astrocytoma, childhood; cerebral astrocytoma / malignant glioma, childhood; cervical cancer; childhood cancer; chronic lymphocytic leukemia; chronic myeloproliferative disorder; clear cell sarcoma of the tendon sheath; colon cancer; colorectal cancer, childhood; cutaneous T-cell lymphoma; endometrial cancer; ependymoma, childhood; epithelial ovarian cancer; esophageal cancer; esophageal cancer, childhood; Ewing's family of tumors; extracranial germ cell tumor, childhood; extragonadal germ cell tumor; extrahepatic bile duct cancer; eye cancer, intraocular melanoma; eye Cancer, retinoblastoma; gallbladder cancer; gastric (gastric / stomach) cancer; gastric (gastric / stomach) cancer, childhood; gastrointestinal carcinoid tumors; extracranial germ cell tumors, childhood; extragonadal germ cell tumors; ovarian germ cell tumors; gestational trophoblastic tumors; brainstem gliomas, childhood; brainstem gliomas, childhood; hairy cell leukemia; head and neck cancer; adult (primary) hepatocellular (liver) cancer; childhood (primary) hepatocellular (liver) cancer; adult Hodgkin's lymphoma (Hodgkin's Lymphoma; Hodgkin's lymphoma in children; Hodgkin's lymphoma in pregnancy; Hypopharyngeal cancer; Gliomas of the hypothalamus and visual pathways in children; Intraocular melanoma; Islet cell carcinoma (endocrine pancreas); Kaposi's sarcoma; Kidney cancer; Laryngeal cancer; Laryngeal cancer in children; Acute lymphocytic leukemia in adults; Acute lymphocytic leukemia in children; Acute myeloid leukemia in adults; Acute myeloid leukemia in children; Chronic lymphocytic leukemia; Chronic myeloid leukemia; Hairy cell leukemia; Lip and oral cancer; Liver cancer in adults (primary); Liver cancer in children (primary); Non-small cell lung cancer; Small cell lung cancer; Acute lymphoblastic leukemia in adults;Acute lymphoblastic leukemia in children; chronic lymphocytic leukemia; AIDS-related lymphoma; (primary) central nervous system lymphoma; cutaneous T-cell lymphoma; Hodgkin's lymphoma in adults; Hodgkin's lymphoma in children; Hodgkin's lymphoma in pregnancy; non-Hodgkin's lymphoma in adults; non-Hodgkin's lymphoma in children; non-Hodgkin's lymphoma in pregnancy; primary central nervous system lymphoma; Waldenstrom's macroglobulinemia; male breast cancer; malignant mesothelioma in adults; malignant mesothelioma in children ; malignant thymoma; medulloblastoma, childhood; melanoma; intraocular melanoma; Merkel cell carcinoma; malignant mesothelioma; metastatic squamous neck carcinoma of unknown primary; multiple endocrine neoplasia syndrome, childhood; multiple myeloma / plasma cell neoplasm; mycosis fungoides; myelodysplastic syndrome; chronic myeloid leukemia; acute myeloid leukemia, childhood; multiple myeloma; chronic myeloproliferative disorder; nasal cavity and paranasal sinus cancer; nasopharyngeal carcinoma; nasopharyngeal carcinoma, childhood; neuroblastoma; non-Hodgkin lymphoma, adult; non-Hodgkin lymphoma, childhood; Non-Hodgkin's lymphoma in pregnancy; non-small cell lung cancer; oral cancer in children; oral cavity and lip cancer; oropharyngeal cancer; osteosarcoma / malignant fibrous histiocytoma of bone; ovarian cancer in children; ovarian epithelial cancer; ovarian germ cell tumors; ovarian low malignant potential tumors; pancreatic cancer; pancreatic cancer in children, islet cell pancreatic cancer; paranasal sinus and nasal cavity cancer; parathyroid cancer; penile cancer; pheochromocytoma; pineal and supratentorial primitive neuroectodermal tumors in children; pituitary tumors; plasma cell neoplasms / multiple myeloma; pleuropulmonary blastoma; pregnancy and breast cancer; pregnancy and Hodgkin's lymphoma ; Pregnancy and non-Hodgkin lymphoma; Primary central nervous system lymphoma; Primary liver cancer, adults; Primary liver cancer, children; Prostate cancer; Rectal cancer; Renal cell (kidney) cancer; Renal cell cancer, children; Transitional cell carcinoma of the renal pelvis and ureter; Retinoblastoma; Rhabdomyosarcoma, children; Salivary gland cancer; Salivary gland cancer, children; Sarcoma, Ewing family of tumors; Kaposi's sarcoma; Sarcoma (osteosarcoma, malignant fibrous histiocytoma of bone; Sarcoma, rhabdomyosarcoma, children; Soft tissue sarcoma, adults; Soft tissue sarcoma, children; Sezary syndrome ( Syndrome; Skin Cancer; Skin Cancer in Children; Skin Cancer (Melanoma); Merkel Cell Skin Cancer; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma in Adults; Soft Tissue Sarcoma in Children; Metastatic Squamous Neck Cancer of Unknown Primary; Gastric (Stomach / Gastric) Cancer; Gastric (Stomach / Gastric) Cancer in Children; Supratentorial Primitive Neuroectodermal Tumor in Children; Cutaneous T-Cell Lymphoma; Testicular Cancer; Thymoma in Children; Malignant Thymoma; Thyroid Cancer; Thyroid Cancer in Children; Transitional Cell Carcinoma of the Renal Pelvis and Ureter; Gestational Trophoblastic Tumor; Cancer of Unknown Primary Site in Children; Rare Childhood Cancers; Transitional Cell Carcinoma of the Ureteropelvis; Urethra Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma in Children; Vulvar Cancer; Waldenstrom's Macroglobulinemia;and Wilms' Tumor. ;

[0072] In certain aspects, the cancer is leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer and breast cancer. In other aspects, the viral infection is selected from the group consisting of: gastroenteritis, fatal encephalitis, encephalitis, fever, arthralgia, meningitis, myocarditis, paralysis, hemorrhagic fever, thrombocytopenia, common cold, mononucleosis, renal or respiratory syndrome, hepatitis, pneumonia, diarrhea, neurological disorders, skin lesions, cutaneous lymphoma, AIDS, skin warts, genital warts, cervical cancer, leukemia, influenza, rash, Merkel cell carcinoma, mumps, poliomyelitis, rubella, Bogosta's disease, chickenpox and / or smallpox.

[0073] "Infectious disease" refers to a disease caused by an infection. An infection is the invasion of a body tissue by a pathogen, its proliferation, and the response of the host tissue to the infectious agent and the toxins it produces. Infectious agents include viruses, viroids, prions, bacteria, nematodes (such as parasitic roundworms and pinworms), arthropods (such as ticks, mites, fleas, and lice), fungi (such as ringworms), and other macroparasites (such as tapeworms and other worms). Thus, as used herein, a short-term infection is an acute infection, while a "chronic infection" refers to a long-term infection or a persistent infection.

[0074] As used herein, "viral infection" refers to any infection or disease caused by a virus. Viruses causing viral infections include, but are not limited to, adeno-associated virus, Aichi virus, Australian bat lyssavirus, BK polyomavirus, Bannavirus, Barmah forest virus, Bunyamwera virus, Bunyavirus La Crosse, Bunyavirus snowshoehare, Cercopithecine herpesvirus, Chandipuravirus, Chikungunya virus, Cosavirus A, Cowpoxvirus, Coxsackievirus, Crimean-Congohemorrhagic fever virus, dengue virus, Dhori virus, Dugbevirus, Duvenhage virus virus), Eastern equine encephalitis virus, Ebola virus, Echovirus, Encephalomyocarditis virus, Epstein-Barr virus, European bat lyssavirus, GB virus C / Hepatitis Gvirus, Hantaan virus, Hendra virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis E virus, Hepatitis D virus, Horsepox virusvirus), human adenovirus, human astrovirus, human coronavirus, human cytomegalovirus, human enterovirus 68, human enterovirus 70, human herpesvirus 1, human herpesvirus 2, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, human immunodeficiency virus, human papillomavirus 1, human papillomavirus 2, human papillomavirus 16, human papillomavirus 18, human parainfluenza virus, human parvovirus B19, human respiratory syncytial virus, human rhinovirus, human SARS coronavirus, human retrovirus, human T-lymphotropic virus, human torovirus, influenza A virus, influenza B virus, influenza C virus, Isfahan virus, JC polyomavirus, Japanese encephalitis virus, Junin arenavirus, KI Polyomavirus, Kunjin virus, Lagos bat virus, Lake Victoria Marburg virus Marburgvirus, Langat virus, Lassa virus, Lordsdale virus, Louping ill virus, Lymphocytic choriomeningitis virus, Machupo virus, Mayaro virus, Middle East respiratory syndrome (MERS) coronavirus, Measles virus Yokuniemi, Mengo encephalomyocarditis virus, Merkel cell polyomavirus, Mokola virus, Molluscum contagiosumvirus, Monkeypox virus, Mumps virus, Murray valley encephalitis virus, New York virus, Nipahvirus, Norwalk virus, O'nyong-nyong virus virus), Orf virus, Oropouche virus, Pichinde virus, Poliovirus, Punta torophlebovirus), Puumala virus, Rabies virus, Rift valley fever virus, Rosavirus A, Ross river virus, Rotavirus A, Rotavirus B, Rotavirus C, Rubella virus, Sagiyama virus, Salivirus A, Sandfly fever sicilian virus, Sapporo virus, Semliki forest virus, Seoul virus, Simian foamy virus, Simian virus 5, Sindbis virus, Southampton virus, St. louis encephalitis virus, Tick-borne powassan virus, Torque teno virus, Toscanavirus, Uukuniemi virus, Vaccinia virus, Varicella-zoster virus, Variola virus, Venezuelan equine encephalitis virus, Vesicular stomatitisvirus, Western equine encephalitis virus, WUpolyomavirus, West Nile virus, Yaba monkey tumorvirus, Yaba-like disease virus, Yellow fever virus, and Zika virus.

[0075] In certain aspects, the compounds inhibit guanosine monophosphate synthetase.

[0076] Guanosine monophosphate synthetase (GMPS) is a two-domain enzyme consisting of a glutamine amidotransferase domain (GAT) and a synthetase domain. The GAT domain hydrolyzes glutamine to produce ammonia, which is transferred to the synthetase domain to react with a nucleotide intermediate to produce GMP. As used herein, the term "GMPS inhibitor" or "GMPSi" refers to any compound capable of inhibiting the enzymatic activity of GMPS, including the glutamine amidotransferase activity of the GAT domain and the synthetase activity of the synthetase domain. Such inhibitors effectively inhibit GMPS and are referred to as "inhibiting", "reducing" or "reducing" the biological activity of GMPS.

[0077] The efficiency of a compound can be referred to by its IC50 value. "IC50" is the half-maximal inhibitory concentration (IC50) of a compound. As used herein, the IC50 of a GMPSi refers to the concentration of the inhibitor that is sufficient to induce inhibition of the enzymatic activity of a GMPS halfway between baseline and maximum after a specified exposure time.

[0078] In additional aspects, the method further comprises administering a chemotherapeutic agent or an antiviral agent.

[0079] The compounds of the present invention can be administered in combination with one or more additional therapeutic agents. The phrases "combination therapy", "in combination with", etc. refer to the use of more than one drug or treatment at the same time to increase the response. The GMPS inhibitors of the present invention can be used, for example, in combination with other drugs or for the treatment of cancer, immune diseases and disorders or viral infections. In various aspects, the compounds are administered before, simultaneously with, or after the administration of the chemotherapeutic agent or antiviral agent.

[0080] The term "anti-cancer therapy" refers to any therapy or treatment that can be used to treat cancer. Anti-cancer therapies include, but are not limited to, surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.

[0081] Examples of chemotherapeutic or anticancer agents include, but are not limited to, Actinomycin, Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Irinotecan, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Teniposide, Tioguanine, Topotecan, Valrubicin, Vinblastine, Vincristine, Vindesine, Vinorelbine, panitumamab, Erbitux (cetuximab), matuzumab, IMC-IIF 8, TheraCIMhR3, denosumab, Avastin (bevacizumab), Humira (adalimumab), Herceptin (trastuzumab), Remicade (infliximab), rituximab, Synagis (palivizumab), Mylotarg (gemtuzumab) oxogamicin), Raptiva (efalizumab), Tysabri (natalizumab), Zenapax (dacliximab), NeutroSpec (technetium (99mTc) fanolesomab), tocilizumab, ProstaScint (Indium-Ill labeled capromab pendetide), Bexxar (tositumomab), Zevalin (ibritumomab conjugated to yttrium-90) tiuxetan (IDEC-Y2B8), Xolair (omalizumab), MabThera (rituximab), ReoPro (abciximab), MabCampath (alemtuzumab), Simulect (basiliximab), LeukoScan (sulesomab), CEA-Scan (arcitumomab), Verluma (nofetumomab), Panorex (edrecolomab), alemtuzumab, CDP870, natalizumab, Gilotrif (afatinib), Lynparza (olaparib), Perjeta (pertuzumab), Otdivo (nivolumab), Bosulif (bosutinib), Cabometyx (cabozantinib), Ogivri (trastuzumab-dkst), Sutent (sunitinib malate), Adcetris (brentuximab vedotin), Alecensa (alectinib), Calquence (acalabrutinib), Yescarta (ciloleucel), Verzenio (abemaciclib), Keytruda (pembrolizumab), Aliqopa (copanlisib), Nerlynx (neratinib), Imfinzi ( zi) (durvalumab), Darzalex (daratumumab), Tecentriq (atezolizumab) and Tarceva (erlotinib). Examples of immunotherapeutic agents include, but are not limited to, interleukins (Il-2, Il-7, Il-12), cytokines (interferon, G-CSF, imiquimod), chemokines (CCL3, CCl26, CXCL7), immunomodulatory imide drugs (thalidomide and its analogs).

[0082] Viral infections can be treated with antiviral drugs that are specific for viral agents. The terms "antiviral drug," "antiviral agent," and the like are used without any distinction and refer to drugs used to inhibit viral development and replication. Antiviral agents also include monoclonal antibody-based antivirals and viricides that can inactivate or destroy viral particles in vivo or in vitro.

[0083] Antiviral agents include, but are not limited to, Abacavir, Acyclovir, Adefovir, Amantadine, Amprenavir, Ampligen, Arbidol, Atazanavir, Atripla, Balavir, Cidofovir, Combivir, Dolutegravir, Darunavir, Delavir dine), Didanosine, Docosanol, Edoxudine, Efavirenz, Emtricitabine, Enfuvirtide, Entecavir, Ecoliever, Famciclovir, Fomivirsen, Fosamprenavir, Foscarnet, Fosfonet, Fusion inhibitors inhibitor、Ganciclovir、Ibacitabine、Imunovir、Idoxuridine、Imiquimod、Indinavir、Inosine、Integrase inhibitor、Interferon type III、Interferon type II、Interferon type I、Interferon、Lamivudine、Lopinavir、Loviride、Maraviroc、Moroxydine、Methisazone、Nelfinavir、Nevirapine、Nexavir、Nitazoxanide、Nucleoside analogs analogues), ritonavir (Norvir), oseltamivir, peginterferon alpha-2a (Peginterferonalfa-2a), Penciclovir, Peramivir, Pleconaril, Podophyllotoxin, Protease inhibitor, Raltegravir, Reverse transcriptase inhibitor, Ribavirin, Rimantadine, Ritonavir, Pyramidine, Saquinavir, Sofosbuvir, Stavudine, Telaprevir, Tenofovir, Tenofovir disoproxil disoproxil, Tipranavir, Trifluridine, Lamivudine, Tromantadine, Truvada, Valaciclovir, Valganciclovir, Vicriviroc, Vidarabine, Viramidine, Zalcitabine, Zanamivir, and Zidovudine.

[0084] In another embodiment, the present invention provides a method of inhibiting an immune response in a subject, the method comprising administering a compound of formula (I) or formula (II) as provided in Table 1 or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof. In certain aspects, the compound is at least one of compounds 1-5 or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof as shown in Table 2.

[0085] The immune system is a system of biological structures and processes that prevent diseases in an organism. This system is a diffusion, complex network of interacting cells, cell products, and cell-forming organizations that protect the body from pathogens and other foreign bodies, destroy infected and malignant cells, and remove cell debris: the system includes the thymus, spleen, lymph nodes and lymphoid tissues, stem cells, leukocytes, antibodies, and lymphokines. B cells or B lymphocytes are a type of lymphocyte in the humoral immunity of the adaptive immune system, and are important for immune surveillance. T cells or T lymphocytes are a type of lymphocyte that plays a key role in cell-mediated immunity. In contrast, B cell antigen-specific receptors are antibody molecules on the surface of B cells, and can identify the entire pathogen without any antigen processing. Each B cell lineage expresses different antibodies, so a complete set of B cell antigen receptors represents all antibodies that the body can make.

[0086] The term "immune response" refers to the overall body response to an antigen, and preferably refers to a cellular immune response or a cellular and humoral immune response. The immune response may be protective / preventive / prophylactic and / or therapeutic.

[0087] In various aspects, the subject suffers from an autoimmune condition, an inflammatory disease, ankylosing spondylitis, or has an organ and tissue transplant. In many aspects, the compound inhibits guanosine monophosphate synthetase.

[0088] "Immune disorder" or "immune disease" refers to any medical condition characterized by a malfunction of the immune system. Autoimmune diseases are characterized by abnormal activation and proliferation of autoreactive T cells and B cells that react with substances and tissues normally present in the body (autoimmunity). Autoantigen reactivity may induce tissue damage or destruction, altered organ growth, and / or altered organ function.

[0089] Autoimmune and inflammatory diseases and disorders include, but are not limited to, acute disseminated encephalomyelitis (ADEM), Addison's disease, agammaglobulinemia, alopecia areata, amyotrophic lateral sclerosis (also known as Lou Gehrig's disease), ankylosing spondylitis, antiphospholipid syndrome, antisynthetase syndrome, arthritis, asthma; atherosclerosis, atopic allergy, atopic dermatitis, autoimmune aplastic anemia, autoimmune cardiomyopathy, autoimmune enteropathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune pancreatitis, autoimmune peripheral neuropathy, autoimmune endocrine polyglandular syndrome, autoimmune progesterone dermatitis, autoimmune thrombocytopenic purpura, autoimmune urticaria, autoimmune uveitis, Balo disease / Balo concentric sclerosis (Balo concentric sclerosis), autoimmune thrombocytopenic purpura, autoimmune urticaria, autoimmune uveitis, Balo disease / Balo concentric sclerosis, ... concentricsclerosis, Behcet's disease disease, Berger's disease, Bickerstaff's encephalitis, Blau syndrome, bullous pemphigoid, cancer, Castleman's disease, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyneuropathy, chronic obstructive pulmonary disease, chronic recurrent multifocal osteomyelitis, Churg-Strauss syndrome, cicatricial pemphigoid, Cogan syndrome, cold agglutinin disease, complement component 2 deficiency, contact dermatitis, cranial arteritis, CREST syndrome, Crohn's disease, Cushing's Syndrome, cutaneous leukocytoclastic vasculitis, Dego's disease, Dercum's disease), dermatitis herpetiformis, dermatitis, type 1 diabetes mellitus, diffuse cutaneous systemic sclerosis, discoid lupus erythematosus, diverticulitis, Dressler's syndrome, drug-induced lupus, eczema, endometriosis, eosinophilic fasciitis, eosinophilic gastroenteritis, eosinophilic pneumonia, epidermolysis bullosa acquisita, erythema nodosum, erythroblastosis fetalis, essential mixed cryoglobulinemia, Evan's syndrome, progressive musculoskeletal disease, fibrosing alveolitis (or idiopathic pulmonary fibrosis), gastritis, gastrointestinal pemphigoid, glomerulonephritis, Goodpasture's syndrome, graft-versus-host disease, gout, Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, Henoch-Schonlein purpura, hepatitis, herpes gestationis (also known as pemphigoid gestationis), hidradenitis suppurativa, Hughes-Stovinsyndrome), hypogammaglobulinemia, idiopathic inflammatory demyelinating disease, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, IgA nephropathy, inclusion body myositis, interstitial cystitis, irritable bowel syndrome, juvenile idiopathic arthritis (also known as juvenile rheumatoid arthritis), Kawasaki's disease, Lambert-Eaton myasthenic syndrome, laryngitis, leukocytoclastic vasculitis, lichen planus, lichen sclerosus atrophicus, linear IgA disease, lupus hepatitis, also known as autoimmune hepatitis, lupus erythematosus, Majeed syndrome, microscopic colitis, microscopic polyangiitis, Miller-Fisher syndrome, mixed connective tissue disease, Morphea, Mucha-Habermann disease, also known as acute pityriasis lichenoides lichenoideset varioliformis acuta), multiple sclerosis, myasthenia gravis, myositis, muscle diseases, Ménière's disease, narcolepsy, nephritis, neuromyelitis optica, neuromyotonia, ocular cicatricial pemphigoid, opsoclonus-myoclonus syndrome, Ord's thyroiditis, relapsing rheumatic disease, PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococci), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis, Parsonage-Turner syndrome, pelvic inflammatory disease, pemphigus vulgaris, perivenous encephalomyelitis, pernicious anemia, pharyngitis, pleurisy, POEMS syndrome, polyarteritis nodosa, polymyalgia rheumatica, polymyositis, primary biliary cirrhosis biliary cirrhosis, primary sclerosing cholangitis, progressive inflammatory neuropathy, prostatitis, psoriasis, psoriatic arthritis, pure red cell aplasia, pyoderma gangrenosum, Rasmussen's encephalitis, Raynaud phenomenon, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, schizophrenia, Schmidt syndromesyndrome), Schnitzler syndrome, scleritis, scleroderma, seborrheic dermatitis, immune complex serum sickness, sinusitis, Sjogren's syndrome syndrome), splenitis, spondyloarthropathies, stiff person syndrome, Still's disease, subacute bacterial endocarditis (SBE), Susac's syndrome, Sweet's syndrome, Sydenham chorea, sympathetic ophthalmia, systemic lupus erythematosus, Takayasu arteritis, temporal arteritis, thrombocytopenia, thyroiditis, Tolosa-Hunt syndrome, transverse myelitis, ulcerative colitis, undifferentiated spondyloarthropathies, urticarial vasculitis, vasculitis, vitiligo, Wegener's granulomatosis, familial Mediterranean fever (FMF), hyperimmunoglobulinemia D with recurrent fever (HIDS), TNF receptor-associated periodic syndrome (TRAPS), Muckle–Wells syndrome (Muckle–Wells syndrome). syndrome) (CAPS, urticarial deafness amyloidosis), familial cold urticaria, neonatal-onset multisystem inflammatory disease, periodic fevers, aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome), Blau syndrome, suppurative sterile arthritis, pyoderma gangrenosum, acne (PAPA), interleukin-1 receptor antagonist deficiency (DIRA), allergic reactions, Crohn's disease, and gout.

[0090] Immunosuppressive drugs or immunosuppressants or anti-rejection drugs are drugs that suppress or prevent the activity of the immune system. Immunosuppressants are used to expect the indications of suppressing the immune system. Such indications include autoimmune diseases (psoriasis, lupus, rheumatoid arthritis, Crohn's disease, multiple sclerosis, alopecia areata, myasthenia gravis, vitiligo, granuloma, sarcoidosis, focal segmental glomerulosclerosis, Behcet's disease, pemphigus, ulcerative colitis), non-autoimmune inflammatory diseases (asthma, allergy), ankylosing spondylitis and organ and tissue transplants. Immunosuppressants include corticosteroids, calcineurin inhibitors, mTOR inhibitors, IMDH inhibitors, biological agents and monoclonal antibodies.

[0091] Examples of specific immunosuppressants include, but are not limited to, prednisone (Deltasone, Orasone), budesonide (Entocort EC), prednisolone (Millipred), cyclosporine (Neoral, Sandimmune, SangCya), tacrolimus (Astagraf XL, Envarsus XR, Prograf), sirolimus (Rapamune), everolimus (Afinitor, Zortress), azathioprine (Azasan, Imuran), leflunomide (Arava), mycophenolate (CellCept, Myfortic), abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab (Cimzia), etanercept (Enbrel), golimumab (golimumab), mab (Simponi), infliximab (Remicade), ixekizumab (Taltz), natalizumab (Tysabri), rituximab (Rituxan), secukinumab (Cosentyx), tocilizumab (Actemra), ustekinumab (Stelara), vedolizumab (Entyvio), basiliximab (Simulect), daclizumab (Zinbryta), and muromonab (Orthoclone OKT3).

[0092] In yet another embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) as provided in Table 1 or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. In certain aspects, the compound is at least one of compounds 1-5 or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof as shown in Table 2.

[0093] "Pharmaceutically acceptable" means that the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. For example, the carrier, diluent or excipient or a combination thereof can be administered to a subject together with the GMPS inhibitor of the present invention without causing any undesirable biological effects or interacting in an undesirable manner with the GMPS inhibitor of the pharmaceutical composition contained therein.

[0094] The following presents examples discussing novel GMP synthetase inhibitors, their effectiveness and efficacy against cancer cells, which have all been considered for the applications discussed. The following examples are provided to further illustrate embodiments of the invention, but are not intended to limit the scope of the invention. Although the following examples are typical methods that may be used, other procedures, methods or techniques known to those skilled in the art may also be used alternatively.

[0095] Examples

[0096] Example 1

[0097] Development of novel guanosine monophosphate synthetase inhibitors

[0098] Guanosine monophosphate synthetase (GMPS) is a two-domain enzyme whose glutaminase domain produces ammonia that is transferred to the synthetase domain to convert XMP to GMP, a nucleotide precursor for RNA. Figure 1 As shown, GMPS plays an important role in cell division and proliferation as well as viral infection.

[0099] Considering the lack of potent and specific GMPS inhibitors, a series of novel compounds were developed and evaluated for their ability to induce inhibition of GMPS enzymatic activity.

[0100] like Figure 2 As shown, the developed compounds have structures as described in two scaffolds (I) and (II). In the general structures (I) and (II), X is N or CH, R1 is (alkyl, acyl, alkoxy, halide, amino, amide, alkenyl and alkynyl), and R2 is (alkyl, acyl, alkoxy, halide, amino, amide, alkenyl and alkynyl).

[0101] like Figure 3As shown, five compounds with compound structures (1-5) based on two scaffolds (I) and (II), 4-anilinoquinazoline or N-phenylbenzamide were synthesized using previously reported conditions and modifications.

[0102] Example 2

[0103] Evaluation of GMPS inhibitor potency

[0104] The potency of the five compounds against recombinant GMPS was tested in an enzymatic assay by monitoring the UV absorbance at 290 nm and by determining the IC50. The obtained IC 50 The three compounds (1, 2 and 4) were expressed as nanomolar IC 50 The chloroacetamide group was found to be essential for the effective binding to GMPS.

[0105] Compound <![CDATA[IC 50 (nM)]]> 1 6.2 2 23 3 >1000 4 98 5 >1000

[0106] Table 3. IC values ​​of compounds against recombinant human GMPS in enzymatic assay 50 value.

[0107] Example 3

[0108] Evaluation of covalent binding of compound 1 to GMPS in living cells

[0109] To evaluate the ability of compounds to bind to GMPS in living cells, the covalent binding of the most potent inhibitor in the series (ie, compound 1) to GMPS in living cells was evaluated.

[0110] HEK293 cells were treated with various concentrations of compound 1 for 20 minutes. Cells were washed with DPBS (Dubelco phosphate buffered saline), harvested by centrifugation, and then lysed using a NP40-based buffer. The resulting cell lysate was subjected to Cu-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with TAMRA azide, followed by SDS PAGE analysis and visualization for TAMRA fluorescence. Figure 4A As shown, a prominent band matching the size of GMP was observed at approximately 75 kDa. This result indicates that compound 1 covalently binds to GMPS, as expected given its observed importance for electrophiles binding to the target. In addition, the dose response indicates that compound 1 covalently binds to GMPS at low nanomolar concentrations, and the binding is saturated at approximately 100 nM.

[0111] To confirm the binding of compound 1 to GMPS, a pull-out experiment was performed with compound 1. The band at 75 kDa was enriched and analyzed by liquid chromatography / mass spectrometry (LC / MS / MS), which confirmed that the band at 75 kDa was indeed GMPS ( Figure 4B ). These data indicate that compound 1 binds efficiently and specifically to GMPS in living cells.

[0112] Example 4

[0113] Evaluation of the efficacy of compound 1 in inhibiting tumor cell survival

[0114] To evaluate the efficacy of compound 1 in inhibiting cancer cell survival, compound 1 was screened against eight different cancer cell lines and the effect on cell proliferation was measured using a viability assay based on the fluorescent dye Sulforhodamin B. Figure 5 As demonstrated, and quantified in Table 4, Compound 1 was found to cause >50% cell death in all eight cell lines tested. These results suggest that GMPS inhibitors such as Compound 1 exhibit broad-spectrum anticancer activity.

[0115]

[0116] Table 4. Effect of Compound 1 on survival in eight different cancer types.

[0117] (Negative values ​​indicate cell death)

[0118] Although the present invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the present disclosure. Accordingly, the present invention is limited only by the following claims.

Claims

1. A compound selected from: or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is selected from the group consisting of: 2-chloro-N-(4-((3-(prop-2-yn-1-yloxy)phenyl)amino)quinazolin-6-yl)acetamide; and 2-chloro-N-(4-((3-methoxyphenyl)amino)quinazolin-6-yl)acetamide.

5. The compound according to claim 1, wherein the compound is 3-(2-chloroacetamido)-N-(3-(prop-2-yn-1-yloxy)phenyl)benzamide.

6. Use of a compound in the preparation of a medicament for treating a disease associated with guanosine monophosphate synthetase, wherein the compound is selected from or a pharmaceutically acceptable salt thereof.

7. The use according to claim 6, wherein the disease or disorder is cancer or viral infection.

8. The use according to claim 7, wherein the cancer is selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, kidney cancer, breast cancer, cervical cancer, leukemia and Merkel cell carcinoma.

9. The use according to claim 7, wherein the viral infection is selected from the group consisting of: gastroenteritis, encephalitis, fever, arthralgia, meningitis, myocarditis, paralysis, hemorrhagic fever, thrombocytopenia, common cold, mononucleosis, renal or respiratory syndrome, hepatitis, pneumonia, diarrhea, neurological disorders, skin lesions, cutaneous lymphoma, AIDS, skin warts, genital warts, influenza, rash, mumps, poliomyelitis, rubella, Pogosta disease, chickenpox and smallpox.

10. The use according to claim 9, wherein the viral infection is fatal encephalitis.

11. A pharmaceutical composition comprising a compound and a pharmaceutically acceptable carrier, wherein the compound is selected from or a pharmaceutically acceptable salt thereof.

Citation Information

Patent Citations

  • Inhibitors of tyrosine kinase

    CN114401722A

  • Quinazoline derivatives as anti-proliferative agents

    US5616582A